Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.RMTG's ISSCA Division Returns to São Paulo for a Second Brazil Congress, November 20-21
RMTG to Go Ringside at BKFC This Weekend to Capture Content for Its "RMTG Brief" Investor-Awareness Campaign
RMTG's ISSCA Division Expands Global Online Academy With Ten New Curriculum Tracks
RMTG Broadens Longevity Footprint With New ISSCA Certification Across Adjunctive Therapies
RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides
RMTG's ISSCA Division to Host ISSCA 125 Global Summit in Cancún, Mexico
RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy
Regenerative Medical Technology Group, Inc. Details Expanded ISSCA AI(TM) Clinical Intelligence Platform, Including Protocol-Native Engine, Structured Data Assets, and Multi-Line Commercial Model
RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements
Cellgenic Establishes Local Commercial Presence in Brazil
RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint
RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions
RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets
RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000
RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions
RMTG Expands Cellgenic's Cancún Laboratory Infrastructure with Two Additional ISO 7 Clean Rooms
RMTG to Hold First-Ever Investor Call to Discuss Second Quarter 2026 Results
RMTG Expands Cellgenic Operations Into Argentina, Establishing a Strategic Commercial Hub for Regenerative Medicine in Latin America
RMTG Launches ISSCA AI(TM) Clinical Intelligence Platform, Extending Its Global Regenerative Medicine Network Into AI-Driven Clinical Infrastructure